An interventional study of Vagus Nerve Stimulation in Treatment Resistant Depression, sponsored by Stanford University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Stanford University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University — 2 open to participants now, 6 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Stanford University.
Among the 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, and was the 12th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →2 of the 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 12 is below the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 35 across the 12 interventional studies, 100 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
1 of the studies in Depressive Disorder, Treatment-Resistant by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Depressive Disorder, Treatment-Resistant by Stanford University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will examine the autonomic, physiologic and neurophysiologic effects of implanted Vagus Nerve Stimulation (VNS) in treatment-resistant depression patients.
The purpose of this study is to examine the autonomic and physiologic effects of implanted VNS in treatment-resistant depression patients. To examine the neurophysiologic effects of Vagus Nerve Stimulation (VNS) in treatment-resistant depression.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must be currently implanted with a VNS device for the clinical indication of Major Depressive Disorder (MDD)
a. Clinical Indication of MDD as defined: Participant has a diagnosis of chronic (≥ 2 years) or ≥ 4 recurrent depressive episodes as defined by criteria documented using the MINI criteria and psychiatric medical record review.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving vagus nerve stimulation through an implanted Vagus Nerve Stimulation Device.
Device: Vagus Nerve Stimulation
Participants receiving vagus nerve stimulation through an implanted Vagus Nerve Stimulation Device.
Gamma and theta band phase-amplitude coupling
Measurement of EEG and ECG to quantify changes in phase-amplitude coupling in the gamma and theta band related to chronic VNS
Time frame: Baseline, Week 6 and Week 19
Heart brain coupling
Measurement of heart brain coupling (heart rate entrainment in response to trains of intermittent theta burst stimulation) with VNS via an EKG sweep
Time frame: Week 19
Heart rate
Measure heart rate and heart rate variability with VNS
Time frame: Baseline, Week 6 and Week 19
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 9 months is below that.
Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →